Dermoscopy Improves Accuracy of Primary Care Physicians to Triage Lesions Suggestive of Skin Cancer by Argenziano, Giuseppe et al.
Dermoscopy Improves Accuracy of Primary Care Physicians
to Triage Lesions Suggestive of Skin Cancer
Giuseppe Argenziano, Susana Puig, Iris Zalaudek, Francesco Sera, Rosamaria Corona, Merce` Alsina,
Filomena Barbato, Cristina Carrera, Gerardo Ferrara, Antonio Guilabert, Daniela Massi, Juan A. Moreno-Romero,
Carlos Mun˜oz-Santos, Gianluca Petrillo, Sonia Segura, H. Peter Soyer, Renato Zanchini, and Josep Malvehy
A B S T R A C T
Purpose
Primary care physicians (PCPs) constitute an appropriate target for new interventions and
educational campaigns designed to increase skin cancer screening and prevention. The aim of this
randomized study was to determine whether the adjunct of dermoscopy to the standard clinical
examination improves the accuracy of PCPs to triage lesions suggestive of skin cancer.
Patients and Methods
PCPs in Barcelona, Spain, and Naples, Italy, were given a 1-day training course in skin cancer
detection and dermoscopic evaluation, and were randomly assigned to the dermoscopy evaluation
arm or naked-eye evaluation arm. During a 16-month period, 73 physicians evaluated 2,522
patients with skin lesions who attended their clinics and scored individual lesions as benign or
suggestive of skin cancer. All patients were re-evaluated by expert dermatologists at clinics for
pigmented lesions. Referral accuracy of both PCP groups was calculated by their scores, which
were compared to those tabulated for dermatologists.
Results
Referral sensitivity, specificity, and positive and negative predictive values were 54.1%, 71.3%,
11.3%, and 95.8%, respectively, in the naked-eye arm, and 79.2%, 71.8%, 16.1%, and 98.1%,
respectively, in the dermoscopy arm. Significant differences were found in terms of sensitivity and
negative predictive value (P  .002 and P  .004, respectively). Histopathologic examination of
equivocal lesions revealed 23 malignant skin tumors missed by PCPs performing naked-eye
observation and only six by PCPs using dermoscopy (P  .002).
Conclusion
The use of dermoscopy improves the ability of PCPs to triage lesions suggestive of skin cancer
without increasing the number of unnecessary expert consultations.
J Clin Oncol 24:1877-1882. © 2006 by American Society of Clinical Oncology
INTRODUCTION
Skin cancer is the most common malignancy in
whites and accounts for about one third of all can-
cers diagnosed per year.1 Melanoma is often lethal
but can usually be cured if diagnosed early. Non-
melanoma skin cancer (including basal cell carci-
noma [BCC] and squamous cell carcinoma [SCC])
is seldom lethal, but if advanced, can cause severe
disfigurement. Earlydetectionand treatment, there-
fore, is the best strategy to reduce mortality and
morbidity associatedwithmelanoma andnonmela-
noma skin cancers, respectively.
The clinical diagnosis of skin cancer is basedon
several morphologic features pertaining to the
shape, elevation, surface, and color of the tumor.
The simple morphologic features summarized by
the asymmetry, border irregularity, color variega-
tion, and diameter  5 mm (ABCD) rule are cur-
rently widely used for diagnosing skin cancer,
particularly melanoma.2 However, ABCD criteria
achieve only 65% to 80% sensitivity.3 The ABCD
rule fails to recognizemelanomas that are small (6
mm)4 or that exhibit regular shape and homoge-
neous color. On the other hand, a variety of benign
pigmented skin lesions mimic melanoma clinically,
resulting in unnecessary excisions.
For diagnosis of skin cancer, dermoscopy has
been shown to be more accurate than naked-eye
examination because dermoscopy allows the visual-
ization of features that are not visible to the naked
eye.5,6 Dermoscopy is currently used by experi-
enced clinicians as a second-level procedure for the
evaluation of selected lesions that were considered
suggestive of skin cancer by the initial clinical exam-
ination.7,8 Under these circumstances, dermoscopy
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has been shown to decrease the number of unnecessary excisions of
benign lesions.9,10 However, no studies have been reported that eval-
uate the impact of dermoscopy as a diagnostic tool for primary care
physicians (PCPs) in a first-level evaluation of nonselected skin tu-
mors. In this setting, theprimarypurposeofdermoscopycouldsimply
be to determine whether a lesion needs to undergo a more detailed
evaluation by experienced clinicians.
To help PCPs use dermoscopy to assess skin tumors and deter-
mine which patients should be given referrals to specialists, we devel-
oped a simplified diagnostic algorithm, known as the three-point
checklist, based on the evaluation of three dermoscopic criteria. In an
earlier study, this algorithm showed good reproducibility and high
sensitivity in the hands of dermoscopy novices.11
The aim of this prospective randomized study was to determine
whetherPCPsachievegreater accuracy to triage skin lesions suggestive
of skin cancer using dermoscopic evaluation and the three-point
checklist in addition to the standard clinical examination.
PATIENTS AND METHODS
This study was conducted inNaples, Italy, and in Barcelona, Spain. The study
designconsistedof four steps (Fig1). In step1 (PCPrecruitment and training),
PCPswere selected andgiven training in identificationof skin cancer using the
ABCD rule and the three-point checklist. In Naples, PCPs from different
geographic areas of the city were invited to participate. In Barcelona, PCPs
were recruited from twoof the largest healthcare cooperatives (seeAppendix).
Only the PCPs who attended the training sessions and who subsequently
screened patients and referred them to the Pigmented Lesion Clinics (PLCs)
were considered participants in the study.
Two identical 1-day training courses (one inNaples and one Barcelona)
were organized for the PCPs. Each course was subdivided in two sessions of 2
hours each. The first part described theABCD rule for the clinical diagnosis of
melanoma and the basic clinical criteria for the recognition of nonmelanoma
skin cancers, including BCC and SCC. The second part described the three-
point checklist, which is a simple dermoscopic algorithm for distinguishing
benign andmalignant tumors.11 This algorithm is based on the recognition of
only three individual features: dermoscopic asymmetry (in color and/or struc-
ture, not in shape), atypical network (pigmented networkwith thick lines and
irregular distribution), andblue-white structures (presence of anyblue and/or
white color within the lesion). For the three-point checklist, the presence of
two or more features suggests malignancy (Fig 2).
In step 2 (PCP allocation and patient screening), the PCPs who com-
pleted the training course were randomly assigned to an arm in which lesions
were evaluated by standard clinical examination or to an arm in which der-
moscopy was used in addition to the naked-eye assessment of skin tumors.
PCPs assigned to the dermoscopy armwere given a hand-held dermatoscope
(Dermlite; 3Gen LLC, Dana Point, CA).
After the PCPs were assigned to an evaluation arm, consecutive patients
asking for screening or exhibiting one or more skin tumors, as seen by the
PCPs at a routine physical examination (patient-finding screening), were
considered for inclusion. In each geographic area, each PCP in both groups
examined the individual lesions and scored the patient outcome, as banal or
suggestiveof skincancer,ona formthat includedananonymous identification
code indicating the referring PCP, the age and sex of the patient, and the
locations of the lesions.
In step3 (expert evaluation), all patientswere re-evaluatedby at least two
melanoma experts in each of two PLCs involved in the study (one in Naples
and one in Barcelona). The individual lesions were evaluated and scored as
banal or suggestiveof skin cancer by the expertswhowereblindedwith respect
to the evaluation arm of the referring PCP.
In step 4 (excision and histopathology), all lesions that were considered
suggestive of skin cancer at PLC were excised and subsequently diagnosed his-
topathologically.Equivocal lesionsbyhistopathologic examinationwere reviewed
by a second independent pathologist (D.M.) and afinal diagnosiswasmade.
Diagnostic accuracy refers to the ability of a physician to identify correctly
a lesion as malignant or benign when the gold standard is the histopathologic
examination. Referral accuracy refers to the ability of a physician to correctly
Fig 1. Flow diagram summarizing the
study procedure. PCP, primary care physi-
cian; PLC, pigmented lesion clinic.
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determine that a lesionmay bemalignant or benignwhen the gold standard is
diagnosis by a second expert clinician.12Given that the aimof our studywas to
verify theabilityofPCPs to identify lesions suggestiveof skincancer for referral
for a second expert opinion, the evaluation performed at PLCs was chosen as
the gold standard. Referral accuracy (in terms of sensitivity, specificity, and
positive and negative predictive values) was thus calculated on the basis of
contingency tablesbetweenoutcomes (banal/suggestiveof skincancer)ofPCP
diagnoses andoutcomes (excision yes/no) of diagnoses by experts at thePLCs.
Unless otherwise indicated, diagnostic measures are calculated by num-
bers of patients, given that theoccurrenceofmore thanone lesion judged tobe
excised in a single patient is a rare event.13 Patients who had been considered
for inclusion by PCPs but did not attend the PLC for re-evaluation were not
included in the analysis.
Differences between the two evaluation armswere tested using t test and
2 test. Regarding prevalence of lesions suggestive of skin cancer (as judged by
PLCs and PCPs) and prevalence of benign and malignant tumors, as diag-
nosed histopathologically, the differences between the two arms were tested
against the null hypothesis of an odds ratio 1.Given the cluster randomized
design, the correlation of responses of each PCP was therefore accounted for
by applying the method of generalized estimating equations with robust esti-
mates of the variance and covariance of estimated coefficients.14 The same
marginal regression modeling framework was used to calculate points and
intervals estimatesanddifferencesbetweenthe twoarms in termsof sensitivity,
specificity, and positive and negative predictive values.15
RESULTS
Eighty-eight PCPs (52 fromNaples and 36 from Barcelona) attended
the training workshops, and 73 PCPs (40 fromNaples and 33 from
Barcelona) participated fully in the study. Of these, 37 were as-
signed to the naked-eye evaluation arm, and 36 to the dermoscopy
evaluation arm.
The study population consisted of 2,522 patients observed dur-
ing a period of 16 months (May 2003 to September 2004). Seven
hundred forty-nine patientswhowere considered for inclusion by the
PCP but were lost for the re-evaluation at the PLC, were not included
in the study. As shown in Table 1, patients were equally distributed in
the two arms of the study (naked-eye and dermoscopy evaluation) in
terms of age, sex, and prevalence of lesions suggestive of skin cancer as
judged at the PLCs. Hence, randomization seemed to reach a homo-
geneous confounder distribution among groups.
Aboutone thirdof thepatients inbotharmshad lesions scoredas
suggestive of skin cancer by PCPs (30.3% naked-eye and 31.5% der-
moscopy; P  .787), whereas only approximately 6% of all patients
had lesions considered suggestive of skin cancer at PLCs (6.3% naked
eye and 6.4% dermoscopy arm; P  .886). This number of lesions
falsely assessed as suspicious byPCPswas responsible for the relatively
lowpositive predictive value achievedbyPCPs inboth arms (Table 1):
11.3%(naked-eye examination) to16.1%(dermoscopyexamination)
of patients referred byPCPs as having lesions suggestive of skin cancer
were indeed judged equivocal at PLC (P  .106). However, 71.3%
(naked-eye arm) and 71.8% (dermoscopy arm) of patientswith banal
lesions were correctly identified by PCPs (specificity; P .915), with
negative predictive values of 95.8% and 98.1% in the naked-eye and
Fig 2. Early melanoma (0.7 mm in thickness) exhibiting only slight asymmetry
by naked eye examination (inset). Dermoscopic observation reveals striking
asymmetry in color and structure, atypical pigment network (left side of the
lesion), and blue-white structures (in the center and right side). The lesion was
thus scored suggestive of skin cancer by the primary care physician.
Table 1. Patient Demographics and Referral Accuracy by Evaluation Group
Characteristic Naked-Eye Evaluation Group Dermoscopy Evaluation Group P
No. of lesions 1,345 (in 1,325 patients) 1,203 (in 1,197 patients) —
Age of patients, years .502
Mean 40 41
Range 2-90 3-94
Females 827 746 .962†
% 62.4 62.3
Prevalence of lesions suggestive of skin cancer, % 6.3 6.4 .886‡
Sensitivity 54.1 79.2 .002‡
95% CI 46.3-61.7 66.9-87.8
Specificity 71.3 71.8 .915‡
95% CI 65.6-76.4 64.1-78.3
Positive predictive value 11.3 16.1 .106‡
95% CI 8.5-14.8 11.4-22.2
Negative predictive value 95.8 98.1 .004‡
95% CI 94.4-96.9 96.8-98.8
t test.
†2 test.
‡Generalized estimating equation (logit).
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dermoscopy arms, respectively (P .004). This means that there was
a low probability that PCPs, especially in the dermoscopy arm, would
fail to refer apatientwith a lesion suggestiveof skin cancer for a second
expert opinion.
Although the two arms did not differ significantly in specificity,
the dermoscopy arm scored significantly higher in sensitivity than did
the naked-eye arm (P .002). Patients with lesions suggestive of skin
cancer were identified correctly in 79.2% of cases in the dermoscopy
arm, compared with 54.1% of cases in the naked-eye arm (Table 1).
As shown in Figure 1 and Table 2, 162 lesions judged to be
suggestive of skin cancer by the experts at PLCs were excised for
histopathologic examination. One-hundred nineteen patients under-
went excisionofone lesion each; ninepatients had two lesions excised;
seven patients had three lesions excised, and one patient had four
lesions excised. Histopathologically, there were no significant differ-
ences in terms of prevalence of benign and malignant tumors in the
two evaluation arms (Table 2). Among the overall population
screened, melanoma and the overall number of malignant tumors
(including melanoma, BCC, and SCC) showed prevalence of 0.5%
and 3.6%, respectively. Among all patients with lesions considered
suggestive of skin cancer by PCPs,melanoma and the overall number
ofmalignant tumors exhibited prevalence of 1.5%and 11.7%, respec-
tively. Of 12 melanomas identified in this study, seven were in situ,
four were early invasive (Breslow thickness 0.75mm), and onewas
thick melanoma (Breslow thickness of 6 mm).
As shown in Figure 1 and Table 3, a similar number of his-
topathologically proven malignant tumors were identified by the
PCPs in the naked-eye and dermoscopy arms (30 and 33 lesions,
respectively). Conversely, 23 malignant tumors (18 BCC, three SCC,
and twomelanomas [one in situ andone6mmthick])weremissedby
PCPs performing naked-eye observation, compared with only six
missed by PCPs using dermoscopy (four BCC, one SCC, and one
melanoma 0.7 mm thick; P .002).
DISCUSSION
The most significant result of this randomized trial is that the use of
dermoscopy allowed PCPs to perform 25.1% better triage of skin
lesions suggestive of skin cancer compared with naked-eye examina-
tion alone (P  .002). PCPs using dermoscopy performed signifi-
cantly better also in terms of negative predictive value (P  .004),
resulting in a low risk (1.9%) for patients with lesions suggestive of
skin cancer not to be referred by PCPs for a second expert opinion.
Approximately 40% of office visits to physicians, at least in the
United States, are to a family practitioner or internist,16 and almost all
physician-detectedmelanomas are discovered by PCPs rather than by
specialists.17 Comparedwith family or self-detection, physiciandetec-
tion is associated with an increased probability of diagnosing thinner
melanomas.18 However, although most melanoma patients have at
least one primary care visit in the year before diagnosis, only 20%
report receiving a skin cancer examination.17 PCPs, therefore, are in a
unique position to perform skin cancer screening, and constitute the
appropriate target for new interventions and educational campaigns
designed to increase skin cancer screening and prevention.
Given that theaimofour studywas toassess the abilityofPCPs to
identify lesions suggestive of skin cancer for referral, the evaluation
performed at PLCswas chosen as the gold standard. PCPsperforming
standard clinical examinationhad referral sensitivity and specificity of
54.1% and 71.3%, respectively. These rates are similar to those re-
ported previously.13,19 By adding dermoscopy to the standard clinical
examination, PCPs achieved significantly better referral sensitivity
(from54.1% to 79.2%;P .002). The latter result occurredwithout a
decrease in specificity (71.8%), suggesting that better triage of possible
malignant skin tumors could occur without increasing the number
of unnecessary expert consultations. Similar results have also been
reported in a previous study based on the evaluation of clinical and
dermoscopic pictures performedby a groupof 74PCPs.20 In the latter
study, PCP who attended a brief dermoscopy training session
Table 2. No. of Benign and Malignant Tumors As Diagnosed by Histopathologic Examination, by Evaluation Group
Lesion Type
Naked-Eye
Evaluation Group
(n  1,345)
Dermoscopy
Evaluation Group
(n  1,203)
Overall
(n  2,548)
GEE (logit) PNo. % No. % No. %
Overall malignant tumors 53 3.9 39 3.2 92 3.6 .692
Melanoma 6 0.4 6 0.5 12 0.5 .778
Basal cell carcinoma 37 2.8 29 2.4 66 2.6 .787
Squamous cell carcinoma 10 0.7 4 0.3 14 0.5 .256
Overall benign tumors 32 2.4 38 3.2 70 2.7 .396
Melanocytic nevi 22 1.6 29 2.4 51 2.0 .339
Seborrheic keratosis 6 0.4 7 0.6 13 0.5 .819
Other benign lesions 4 0.3 2 0.2 6 0.2 .537
Abbreviation: GEE, generalized estimating equation.
Table 3. No. of Malignant Tumors As Diagnosed by Histopathologic
Examination, by Outcome Scored by Primary Care Physician
Lesion Type
Naked-Eye Evaluation
Group
Dermoscopy
Evaluation Group
Banal
Lesion
Lesion
Suggestive
of Skin
Cancer
Banal
Lesion
Lesion
Suggestive
of Skin
Cancer
Overall malignant tumors 23 30 6 33
Basal cell carcinoma 18 19 4 25
Squamous cell carcinoma 3 7 1 3
Melanoma 2 4 1 5
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achieved improved sensitivity without a decrease in specificity for the
diagnosis of melanoma compared with a control group.
In our study, PCPs who performed dermoscopic examination
after a brief training course had better results in both positive and
negative predictive values (16.1% and 98.1%, respectively) than did
PCP performing naked-eye examination (positive predictive value,
11.3%; negative predictive value, 95.8%). It is noteworthy that a rela-
tively low positive predictive value (13.7%) has also been reported in
an expert setting (PLCs) where diagnostic accuracy was tested in a
population with a relatively low prevalence of melanoma.21
Interestingly, the dermoscopy algorithm taught to PCPs in our
study, namely the three-point checklist, was originally developed for dif-
ferentiation of pigmented skin tumors.11 However, a considerable num-
berofnonmelanomaskincancers, includingnonpigmented lesions,were
correctly identified by the PCPs using dermoscopy. Thus, it could be
speculatedthat the increaseddedicationofPCPstothepatients,asinequa
non condition to perform dermoscopy, was in itself one of the main
reasons for the increased detection of suspected skinmalignancies.
A good skin-cancer screening test should be available to all indi-
viduals with skin tumors to identify thosewho are at high risk for skin
cancer.We propose that dermoscopy be used in clinicalmanagement
of patientswith skin tumors as a first-line screening tool.Dermoscopy
is a valid, simple, and safe method for PCPs to identify high-risk
lesions that require further examination by experts. As a first-level
screening tool, dermoscopy may help PCPs in performing better de-
tection of skin tumors suggestive of skin cancer (increased referral
sensitivity),asdemonstratedinthis study.Asasecond-levelprocedurefor
clinically equivocal lesions, dermoscopy performed by expert clinicians
can reduce thenumberof unnecessary excisions of benign lesions (better
specificity thannaked-eye examination), as previously demonstrated.9,10
Evidence is lacking that skin examination for cancer screening is
effective in reducing mortality or morbidity from skin tumors.22
However, it has also been claimed that “no one should die of malig-
nantmelanoma”23 because “melanomawrites itsmessage on the skin
with its own ink, and it is there for all to see.”24 Dermoscopymay help
clinicians to better recognize this ink.
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